摘要
目的探讨沙利度胺联合吉西他滨+顺铂(GP)方案化疗对晚期非小细胞肺癌(NSCLC)患者生存时间和生存质量的影响。方法根据治疗方法的不同将78例晚期NSCLC患者分为研究组(n=41)和对照组(n=37),研究组患者接受沙利度胺联合GP方案化疗,对照组患者接受单纯GP方案化疗。随访18个月,观察并比较两组患者的生存情况、卡氏功能状态(KPS)评分及不良反应发生情况。结果随访18个月,经Log-rank检验,研究组和对照组患者的生存情况比较,差异无统计学意义(P﹥0.05)。治疗前,研究组和对照组患者的KPS评分比较,差异无统计学意义(P﹥0.05);治疗6个月和治疗12个月后,研究组患者的KPS评分均明显高于对照组(P﹤0.01)。研究组中,脱发(95.12%)和乏力(90.24%)的发生率较高;对照组中,脱发(91.89%)和肝功能异常(89.19%)的发生率较高。研究组患者恶心呕吐、肝功能异常的发生率明显低于对照组,嗜睡的发生率明显高于对照组,差异均有统计学意义(P﹤0.01)。结论沙利度胺联合GP方案化疗能够改善晚期NSCLC患者的生存质量,降低部分不良反应的发生率,但其对生存时间的影响还需扩大样本量、延长随访时间进一步观察。
Objective To observe the effect of thalidomide combined with gemcitabine + cisplatin (GP) on survival time and quality of life in patients with advanced non- small cell lung cancer (NSCLC). Method 78 patients with advanced NSCLC were divided into study group (n=41) and control group (n=37) according to different treatment. Patients were administered thalidomide combined with GP chemotherapy in the study group, and GP chemotherapy alone in the control group. The follow- up period was 18 months and the survival condition, Karnofsky performance status (KPS) score and the incidence of adverse reactions were observed and compared between the two groups. Result After 18- month follow-up, Log-rank test showed that there was no significant difference in survival condition between two groups (P>0.05). Before treatment, there was no significant difference in KPS score between two groups (P>0.05). After treatment for 6 months and 12 months, the KPS score of the study group was significantly higher than that of the control group (P<0.01). The incidence of alopecia (95.12%) and fatigue (90.24%) was higher in the study group, while higher incidence of hair loss (91.89%) and abnormal liver function (89.19%) in the control group. The incidence of nausea/vomitting and abnormal liver function in the study group was signifcantly lower than that in control group, however, the incidence of somnolence significantly higher than that in control group (P<0.01). Conclusion Thalidomide combined with GP chemotherapy can significantly improve the quality of life in patients with advanced NSCLC, and reduce incidence of some adverse reactions. However, the effect on survival time need to be observed further with increased sample size and prolonged follow-up.
作者
姚丽鸽
王留晏
周寒丽
段方方
陈露
张克克
YAO Lige;WANG Liuyan;ZHOU Hanli;DUAN Fangfang;CHEN Lu;ZHANG Keke(Department of Oncology, the Third People’s Hospital of Zhengzhou, Zhengzhou 450000, He’nan, China)
出处
《癌症进展》
2019年第12期1400-1403,共4页
Oncology Progress
基金
郑州市2015年度科技发展计划项目(20150042)
关键词
沙利度胺
非小细胞肺癌
生存期
生存质量
thalidomide
non-small cell lung cancer
survival time
quality of life
